Here's all you need to know about India's first of its kind Covid vaccine: The iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.
This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results. The vaccine was developed in partnership with Washington University, St.
Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in preclinical studies for efficacy.
The intranasal vaccine is stable at 2-8°C for easy storage and distribution and has been designed for efficient distribution and easy pain free administration.